跳至主要内容
临床试验/NCT05552443
NCT05552443终止4 期

Identification of the Optimal Analgesic Dose of Intrathecal Hydromorphone for Pediatric Patients Undergoing Posterior Spine Surgery for Idiopathic Scoliosis

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2023年3月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
Mayo Clinic
入组人数
31
试验地点
1
主要终点
Pain intensity

研究概览

简要总结

The purpose of this study is to identify a dose of intrathecal hydromorphone (opioid pain medicine) that optimizes pain control but minimizes side effects historically seen with this class of pain medications.

详细描述

This study is a sequential coin based up-down dose allocation method with the goal of identifying the ED90 for intrathecal hydromorphone (ITH) in idiopathic adolescent scoliosis repair via the posterior approach. A starting dose of 3.5 mcg/kg of hydromorphone was determined by current practice at the institution as well as upon review of available literature of previously used ITM doses in pediatric spine patients. Subsequent participants will receive higher (step "up") or lower (step "down") from this starting dose. Steps "down" from the starting dose will be smaller than steps "up" to ensure maintenance of adequate analgesia and to allow more accurate estimate of the optimal dose should it decrease beyond our starting dose. Steps "up" from the starting dose were chosen based on commonly used weight-based doses in our current practice. A maximum dose of 400 mcg, despite patient weight, was determined based on expert consensus and review preparatory to research query. Each patient was assigned to a weight-based dose arm, between 3.5mcg/kg-7.0mcg/kg or up to a maximum of 400 mcg. The anesthesiologist covering the case (high lumbar or thoracic corrections) or the surgeon (low lumbar corrections) will administer the medication at the low lumbar level.

ITH dose adjustments for subsequent study patients will be based on the efficacy of the dose used with the prior patient. Efficacious ITH administration will be defined as all NRS scores ≤5 within the first 18 hours after administration (binary outcome). If the NRS score was >5 within 18 hours or if the patient required supplemental opioid administration for pain control (suggestive of insufficient analgesia), the dose will be increased for the next enrolled study patient. If the pain score remains ≤5 within 18 hours of opioid administration, the next patient will receive the next lower dose or the same dose as the previous patient. Patients excluded after randomization will be removed from the study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Sequential
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
10 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • - Undergoing spinal surgery with a posterior approach for idiopathic scoliosis.

排除标准

  • Patients with pre-surgical elevated pain scores (≥ 3/10 on Numeric Rating Scale (NRS)), history of chronic pain, or pre-surgical opioid use will not be included.
  • Patients with contraindications to spinal anesthesia (anatomical abnormality or elevated bleeding or infection risks) will not be included.
  • Patients for whom the protocol is violated (inability to perform postoperative data collection), or the study/procedure was aborted will not be included in analysis.

研究组 & 干预措施

Intrathecal Hydromorphone 2.5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 2.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 2.5 mcg/kg (Drug)

Intrathecal Hydromorphone 3 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 3 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 3 mcg/kg (Drug)

Intrathecal Hydromorphone 2.75 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 2.75 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 2.75 mcg/kg (Drug)

Intrathecal Hydromorphone 3.25 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 3.25 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 3.25 mcg/kg (Drug)

Intrathecal Hydromorphone 5.5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 5.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 5.5 mcg/kg (Drug)

Intrathecal Hydromorphone 6 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 6 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 6 mcg/kg (Drug)

Intrathecal Hydromorphone 6.5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 6.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 6.5 mcg/kg (Drug)

Intrathecal Hydromorphone 7 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 7 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 7 mcg/kg (Drug)

Intrathecal Hydromorphone 5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 5 mcg/kg (Drug)

Intrathecal Hydromorphone 4 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 4 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 4 mcg/kg (Drug)

Intrathecal Hydromorphone 3.5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 3.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 3.5 mcg/kg (Drug)

Intrathecal Hydromorphone 4.5 mcg/kg

Experimental

Subjects undergoing posterior spinal surgery will receive 4.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level

干预措施: Hydromorphone 4.5 mcg/kg (Drug)

结局指标

主要结局

Pain intensity

时间窗: 18 hours after intrathecal hydromorphone administration

Reported by the patient using an 11-point numeric visual analogue scale (NRS) with 0=no pain and 10=worst pain ever

Pain Intensity (Area Under the Curve Pain)

时间窗: 18 hours after intrathecal hydromorphone administration

Pain intensity reported during the first 18 hours after intrathecal opioid administration. Reported by the patient using an 11-point numeric visual analogue scale (NRS) with 0=no pain and 10=worst pain ever. Subjects were asked to rate their pain approximately 9 different times within the first 18 hours after intrathecal hydromorphone administration. The sum of the patients' pain scores was calculated to determine pain intensity. Total scores ranging from 0 to 90 with higher scores indicating more severe pain. Pain scores over the first 18 hours were used to calculate the Area Under the Curve (AUC) using the trapezoidal rule.

次要结局

  • Incidence of antiemetic use postoperatively(24 postoperative hours)
  • Incidence of need for dual anti-pruritic agents(24 postoperative hours)
  • Maximum pain scores(24 hours after intrathecal hydromorphone administration)
  • OME consumption(24 hours after intrathecal hydromorphone administration)
  • Number of Subjects Needing Dual Anti-pruritic Agents(24 postoperative hours)
  • Maximum Pain Scores(18 hours after intrathecal hydromorphone administration)
  • Oral Morphine Equivalents Consumption(24 hours after intrathecal hydromorphone administration)
  • Number of Subjects Needing Antiemetic Medications Postoperatively(24 postoperative hours)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Kathryn (Katie) S. Handlogten

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验